DAK Gesundheit Tender

Contract notice: Conclusion of a non-exclusive discount agreement according to section 130a (8) sgb v for the active ingredient colecalciferol + sodium fluoride, Atc a11cc80, For the period december 1, 2020 - november 30, 2022 The DAK-G assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and therefore the non-discriminatory access option for all pharmaceutical companies. Regardless of this, it ends automatically with the entry into force of the exclusive contract for colecalciferol + sodium fluoride, ATC A11CC80, as a result of a formal award procedure according to the regulations of Part 4 of the GWB with one or more contractual partners. In order to do justice to the diversity of potential contractual partners within the framework of the approval model, every pharmaceutical company is able to conclude a framework agreement at any time and under the same conditions during the term of the contract. The contract documents required for this are available for download from the online portal www.dtvp.de/center under the link given under I.3). The prerequisites for the conclusion or subsequent accession to the contracts that will come into force for the first time on December 1st, 2020 is the complete and timely submission of the following evidence / declarations / attachments (available for download under the link mentioned under I.3) to the following listed contact person at DAK-G: 1. Offer letter, 2. Current evidence of entry in the professional or commercial register (see III.1.1)), 3. Self-declaration of the company (Annex A1) that none of the exclusion criteria according to Sections 123, 124 GWB are present (see III.1.1)), 4. Self-declaration that those medicinal products for which the interested party would like to conclude a contract within the framework of this procedure have a medicinal product approval and that the bidder is entitled to sell at the start of the contract (Annex A2) (see III.1.1)), 5. Self-declaration by the company that the legal requirements for minimum wages and tariff compliance are observed and adhered to (Annex A3) (see III.1.1) 6. Recognition of the contractual stipulations of DAK-Gesundheit, in particular the given discounts, by signing the contract with a company stamp (2 copies in the original) by the interested party at the designated point, 7. The completed Annexes 1 and 2 to the contract (two copies of the original). The interested party has to enter the drugs for the above-mentioned active substance, which are to be the subject of the contract, 8. Effective prequalification notification from DAK-Gesundheit (see III.1.1) and III.1.2)). The documents must be submitted by post to: DAK health Henri Affinass (0032 00) Nagelsweg 27-31 20097 Hamburg Attachment 2 must also be sent as an Excel file to the email address am_rabattvertraege@dak.de . Contracts